Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)

NCT07507825 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Intervention for Venetoclax
DRUG: Intervention for Homoharringtonine
DRUG: Intervention for Azacitidine
DRUG: Intervention for G-CSF

Sponsor

First People's Hospital of Hangzhou

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]